Pacific Biosciences stock outperformed S&P 500 and Medical sector, gaining 6.51% in the past month.

From Nasdaq.: 2024-09-13 18:15:08

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.81, up +0.56% from the previous day, outperforming the S&P 500. The stock has gained 6.51% in the past month, surpassing the Medical sector and S&P 500. Analysts anticipate EPS of -$0.20 and revenue of $41.9 million in the upcoming financial report.

The Zacks Consensus Estimates predict full-year earnings of -$0.95 per share and revenue of $168.07 million for Pacific Biosciences of California. Recent analyst estimates have been revised, indicating optimism about the company’s future. The Zacks Rank system, currently at #3 (Hold) for PACB, shows a 9.17% decrease in consensus EPS estimates in the last 30 days.

The Medical – Instruments industry, which includes PACB, ranks 63 out of 250+ industries, placing it in the top 25%. Zacks Industry Rank demonstrates that the top-rated industries outperform the bottom half significantly. Investors are urged to monitor Zacks.com for stock-moving metrics to track market trends and performance.

Zacks Investment Research recommends a top semiconductor stock that has strong earnings growth and a growing customer base poised to benefit from the increasing demand for AI, Machine Learning, and IoT technologies. The global semiconductor industry is expected to grow from $452 billion in 2021 to $803 billion by 2028, providing ample opportunities for semiconductor companies.



Read more at Nasdaq.: Pacific Biosciences of California (PACB) Surpasses Market Returns: Some Facts Worth Knowing